Innate Pharma (IPHYF) Stock Price, News & Analysis

Company Overview

Innate Pharma is a clinical‐stage biotechnology company specializing in the discovery and development of novel immunotherapies that harness the body’s innate immune system to fight cancer. The company focuses on monoclonal antibodies that target key receptors and ligands involved in immune regulation, aiming to restore natural anti‐tumor responses. Its research platform integrates proprietary antibody engineering and screening technologies to identify therapeutic candidates with optimized efficacy and safety profiles.

The company’s lead programs include monalizumab, an anti‐NKG2A checkpoint inhibitor in collaboration with AstraZeneca, and lacutamab, an anti‐KIR3DL2 antibody for T‐cell lymphomas. In addition to these advanced assets, Innate Pharma’s pipeline features earlier‐stage candidates such as IPH5201, targeting CD39, and IPH4102, directed against KIR3DL2 in rare hematologic malignancies. Through strategic partnerships with major pharmaceutical firms, the company leverages external expertise and resources to accelerate clinical development and global commercial potential.

Founded in 1999 and headquartered in Marseille, France, Innate Pharma is led by Chief Executive Officer Mondher Mahjoubi and a team of seasoned executives with deep experience in oncology drug development. The company maintains research facilities in Europe and the United States, supporting a global footprint that extends across North America, Europe, and Asia. Since its initial public listing on Euronext Paris, Innate Pharma has built a reputation for pioneering innate immunology and advancing novel therapeutic modalities to address unmet needs in oncology.

Key Stats

• Today's Range: $1.31 to $1.31
• 50-Day Range: $1.31 to $1.95
• 52-Week Range: $1.31 to $1.95
• Volume: N/A
• Average Volume: 38 shs
• Market Capitalization: $109.82 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Innate Pharma Stock Analysis - MarketRank™

Innate Pharma scored higher than 9% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for Innate Pharma.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Book Value per Share Ratio

Innate Pharma has a P/B Ratio of 11.91. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.00% of the float of Innate Pharma has been sold short.

Short Interest Ratio / Days to Cover

Innate Pharma has a short interest ratio ("days to cover") of 1, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Innate Pharma has recently decreased by 91.67%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Innate Pharma does not currently pay a dividend.

Dividend Growth

Innate Pharma does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

0.00% of the float of Innate Pharma has been sold short.

Short Interest Ratio / Days to Cover

Innate Pharma has a short interest ratio ("days to cover") of 1, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Innate Pharma has recently decreased by 91.67%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 0.0 / 5
• News Sentiment: N/A

News Coverage This Week

MarketBeat has tracked 1 news article for Innate Pharma this week, compared to 0 articles on an average week.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Innate Pharma insiders have not sold or bought any company stock.

Percentage Held by Insiders

31.89% of the stock of Innate Pharma is held by insiders. A high percentage of insider ownership can be a sign of company health.

IPHYF Stock Analysis - Frequently Asked Questions

How have IPHYF shares performed this year?

Innate Pharma's stock was trading at $2.90 at the beginning of the year. Since then, IPHYF stock has decreased by 54.8% and is now trading at $1.31.

How do I buy shares of Innate Pharma?

Shares of IPHYF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

• Today: 7/16/2025
• Next Earnings (Estimated): 9/17/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: MED - DRUGS
• Sub-Industry: N/A
• Current Symbol: OTCMKTS:IPHYF
• Previous Symbol: NASDAQ:IPHYF
• CIK: 1598599
• Web: www.innate-pharma.com
• Phone: (343) 030-3030
• Fax: 33-04-30-30-30-00
• Employees: 179
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 2.60
• Quick Ratio: 2.60

Sales & Book Value

• Annual Sales: $21.77 million
• Price / Sales: 5.04
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.11 per share
• Price / Book: 11.91

Miscellaneous

• Outstanding Shares: 83,830,000
• Free Float: 57,097,000
• Market Cap: $109.82 million
• Optionable: Not Optionable
• Beta: 0.50